Vés al contingut

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma

Obert
  • Codi protocol: INCB001158-206
  • Codi EudraCT: 2018-004076-35
  • Servei: Hematologia i Hematoteràpia
  • Investigador/a principal:  Gironella Mesa, Mercedes
  • Malaltia: Tumors
  • Fase: Fase I